Detalhe da pesquisa
1.
The rapidly evolving landscape of HCC: Selecting the optimal systemic therapy.
Hepatology
; 2023 Sep 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37695554
2.
Insights for clinical management from the real-life data of the centralized West of Scotland biliary cancer clinic.
BMC Cancer
; 24(1): 597, 2024 May 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38755562
3.
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data.
Liver Int
; 43(8): 1803-1812, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37452505
4.
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study.
Target Oncol
; 19(3): 359-370, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38691295
5.
Pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights.
Curr Oncol
; 30(4): 3871-3885, 2023 03 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-37185406
6.
Safety and Efficacy of Atezolizumab and Bevacizumab Combination as a First Line Treatment of Advanced Hepatocellular Carcinoma.
J Hepatocell Carcinoma
; 10: 1689-1708, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37808223
7.
Immunotherapy in hepatocellular carcinoma: how will it reshape treatment sequencing?
Ther Adv Med Oncol
; 15: 17588359221148029, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36643654
8.
Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience.
Ther Adv Med Oncol
; 15: 17588359231171574, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37457302
9.
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma.
Hepatol Int
; 17(4): 904-914, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37005953
10.
Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights.
J Hepatocell Carcinoma
; 9: 1011-1027, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36128575
11.
The dual checkpoint blockade in unresectable hepatocellular carcinoma: opportunities emerging in clinical trials.
Expert Opin Investig Drugs
; 31(4): 425-435, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35152830
12.
Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials.
Expert Opin Investig Drugs
; 31(4): 401-413, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35072565
13.
Determinants of Treatment Benefit and Post-Treatment Survival for Patients with Hepatocellular Carcinoma Enrolled in Second-Line Trials after the Failure of Sorafenib Treatment.
J Pers Med
; 12(10)2022 Oct 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-36294865
14.
Current options and future directions of systemic therapy for advanced biliary tract cancer.
Explor Target Antitumor Ther
; 2(5): 416-433, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-36045701
15.
Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma.
Expert Rev Anticancer Ther
; 21(9): 927-939, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34167423
16.
Side effects of adjuvant chemotherapy and their impact on outcome in elderly breast cancer patients: a cohort study.
Future Sci OA
; 6(9): FSO617, 2020 Aug 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33235809
17.
Review of immune therapy in HCC: Where are we now and what is the future?
Clin Liver Dis (Hoboken)
; 23(1): e0149, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38881724